The Development of the Economic Model of the Drug Supply of the Population

Разработка экономической модели лекарственного обеспечения населения

Avxentieva, Maria (Авксентьева, Мария) (), Omelyanovsky, Vitaly (Омельяновский, Виталий) () and Sura, Maria (Сура, Мария) ()
Additional contact information
Avxentieva, Maria (Авксентьева, Мария): Russian presidental academy of national economy and public administration (RANEPA)
Omelyanovsky, Vitaly (Омельяновский, Виталий): Russian presidental academy of national economy and public administration (RANEPA)
Sura, Maria (Сура, Мария): Russian presidental academy of national economy and public administration (RANEPA)

Published Papers from Russian Presidential Academy of National Economy and Public Administration

Abstract: The authors performed clinical and economic modeling of the introduction of outpatient drug supply of working age patients with arterial hypertension (AH) in view of adherence to treatment in the Russian Federation and made proposals that increase the efficiency of drug supply programs while containing costs. According to a systematic review of research, provided that patients medications for ?80% of days treatment period, the frequency of hospitalizations in patients with cardiovascular disease can be reduced by 1.43 times. By reducing the frequency of hospitalizations reduced the burden on the state management of patients with hypertension, including costs associated with hospitalization, medical emergencies (direct medical costs), the payment of temporary disability benefits (direct non-medical costs), as well as the loss of gross domestic product (indirect costs). Despite significant cost savings by reducing the frequency of hospital admissions - 4.5 billion rubles per year for a group of 5 million people (registered patients of working age with hypertension in the Russian Federation), the necessary amount of additional funds in the case of implementation of the program of outpatient drug supply will be from 3.3 billion rubles to 22.8 billion rubles in year depending on the price of drugs and the chosen strategy of public funding. However, in certain segments of patients (eg, pharmacotherapy of patients of working age with stage I hypertension) introducing mechanisms to cover the costs of drug therapy by the state can be cost-effective in the short term (1 year). Additional economic benefits of public investment in this amount of 91.7 million rubles up to 802.5 million rubles.

Keywords: health care; financing; health policy; Russia; budget (search for similar items in EconPapers)
Pages: 29 pages
Date: 2015-09-20
New Economics Papers: this item is included in nep-cis and nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
https://repec.ranepa.ru/rnp/ppaper/om06.pdf
Our link check indicates that this URL is bad, the error code is: 404 Not Found

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:rnp:ppaper:om06

Access Statistics for this paper

More papers in Published Papers from Russian Presidential Academy of National Economy and Public Administration Contact information at EDIRC.
Bibliographic data for series maintained by RANEPA maintainer ().